c

Tirzepatide subcutaneous injection for type 2 diabetes

24th March 2024 by Dr Louise Hudman

Tirzepatide subcutaneous injection for type 2 diabetes

NICE released guidance on the use of tirzepatide for diabetes in October 2023.

What is tirzepatide?

Tirzepatide is an agonist at both the GLP-1 receptor (glucagon-like peptide 1) and the GIP receptor (glucose-dependent insulinotropic polypeptide). Stimulation of these receptors causes an increase in the release of GLP-1 and GIP and these in turn cause an increased release of insulin, a reduced glucagon release and delayed gastric emptying.

It both improves diabetes control and increases weight loss.

Read more

No credit card details needed – it takes two minutes.

Join free trial

Login

Already a member? Login to view this content.

Login

Related content

"LocumDeck has been a very useful platform for me as I have only started being a GP locum from March this year. The transition from salaried GP to GP locum was smooth for me due to LocumDeck. It has been a very useful platform for me to get bookings and also to keep on top of the administrative side including invoices. It is very easy to manage my availability and terms and conditions which otherwise would be a difficult matter for a GP locum to go through during each booking. I also have used the FAQ section for help with pensions and other issues with GP locum work and have found this very useful. "

Dr Athira Vijay, GP locum, Chelmsford

See the full list of features within our NASGP membership plans

Membership